Skip to content

13F-HR filed by ACUTA CAPITAL PARTNERS, LLC

ACUTA CAPITAL PARTNERS, LLC filed this 13F-HR for the quarter ended 2019-09-30, filed 2019-11-14, with 31 holding rows worth $138,544,000.

Accession
0001493152-19-017093
Filed
2019-11-14
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q3 2019

A holdings report, 31 entries on the cover page, a total value of $138,544,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $138,544,000 with VALUE read as thousands by filing date, 13F file number 028-16527. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
KADMON HLDGS INC48283N106COM6,412,500$16,160,000thousands by filing date
IOVANCE BIOTHERAPEUTICS INC462260100COM727,500$13,241,000thousands by filing date
ARVINAS INC04335A105COM566,500$12,208,000thousands by filing date
SPDR SER TR78464A870S&P BIOTECH150,000$11,438,000thousands by filing dateput
ARROWHEAD PHARMACEUTICALS IN04280A100COM387,500$10,920,000thousands by filing date
AXSOME THERAPEUTICS INC. COM05464T104Stock522,500$10,575,000thousands by filing date
Milestone Pharmaceuticals Inc59935V107COM369,500$6,891,000thousands by filing date
XENON PHARMACEUTICALS INC COM98420N105Stock702,500$6,330,000thousands by filing date
CRISPR THERAPEUTICS AG NAMEN AKTH17182108Stock134,000$5,493,000thousands by filing date
PROTAGONIST THERAPEUTICS74366E102COM418,500$5,026,000thousands by filing date
BELLUS HEALTH INC NEW07987C204COM785,000$5,016,000thousands by filing date
AURINIA PHARMACEUTICALS INC COM05156V102Stock850,000$4,539,000thousands by filing date
INSMED INC COM PAR $.01457669307Stock220,000$3,881,000thousands by filing date
REATA PHARMACEUTICALS INC75615P103CL A45,000$3,613,000thousands by filing date
VERACYTE INC COM92337F107Stock112,500$2,700,000thousands by filing date
ARGENX SE SPONSORED ADR04016X101ADR22,500$2,564,000thousands by filing date
KARYOPHARM THERAPEUTICS INC48576U106COM237,500$2,285,000thousands by filing date
IRIDEX CORP462684101COM1,171,300$2,167,000thousands by filing date
AMARIN CORP PLC023111206SPONS ADR NEW100,000$1,516,000thousands by filing date
KURA ONCOLOGY INC COM50127T109Stock95,000$1,441,000thousands by filing date
MIRATI THERAPEUTICS INC60468T105COM17,000$1,324,000thousands by filing date
ZYMEWORKS INC98985W102COM52,500$1,302,000thousands by filing date
RA PHARMACEUTICALS INC74933V108COM55,000$1,301,000thousands by filing date
ASSEMBLY BIOSCIENCES INC045396108COM131,500$1,293,000thousands by filing date
MERUS N VN5749R100COM69,274$1,234,000thousands by filing date
PTC THERAPEUTICS INC69366J200COM36,000$1,218,000thousands by filing date
AMICUS THERAPEUTICS INC03152W109COM140,000$1,123,000thousands by filing date
Applied Therapeutics Inc03828A101Common Stock83,000$912,000thousands by filing date
KALVISTA PHARMACEUTICALS INC483497103COM25,000$290,000thousands by filing date
SUNESIS PHARMACEUTICALS INC867328700COM400,000$288,000thousands by filing date
CHEMBIO DIAGNOSTICS163572209COM41,667$255,000thousands by filing date

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001493152-19-017093this filing2019-11-14acceptance time not in the bulk data set